Bulletin on Drug Safety - Current Issue 4/2019 Published
The Bulletin on Drug Safety is a cooperation between the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) and the Paul-Ehrlich-Institut (PEI). The quarterly publication provides information on current aspects of the risk assessment of drugs from both federal institutes. It focuses on pharmacovigilance – the continuous monitoring and evaluation of drug safety before and after marketing authorisation. The Bulletin includes articles on individual drugs as well as background information for understanding pharmacovigilance and research in this area.
The publication is available in German language.
Topics of the Current Issue
- Editorial – New website of the Paul-Ehrlich-Institut
- Methotrexate and the risk of medication errors
- Thyrostatic treatment of Graves' disease during pregnancy
- PML risk when treating multiple sclerosis with Tysabri in anti-JCV antibody positive patients depending on the dosing interval
- Presentation of the EMPAR health care study
- Reports from BfArM and PEI
- PRAC recommendations within the framework of EU referral procedures - October to December 2019
- Revision of the wording of the product information - extracts from the PRAC recommendations on signals
- References to 'Dear Doctor Letter' (Rote-Hand-Brief) and safety information
Further information
Bulletin on Drug Safety, Issue 4/2019 (German only)
www.pei.de/bulletin-safety